Business Context and Reporting Period
This Form 8-K is a current report filed by Oramed Pharmaceuticals Inc. on December 31, 2025. The filing addresses a corporate governance event regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a personnel announcement and does not contain financial statements or performance data.
Material Changes
The material change reported is the resignation of Leonard Sank from the Board of Directors, effective January 1, 2026. Mr. Sank served on the Board for 18 years. The Company explicitly states that the resignation did not result from any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. No specific risks, contingencies, or unusual items are disclosed in this document beyond the standard departure of a director.
Key Facts for Investor Verification
- Leonard Sank is resigning from the Board effective January 1, 2026.
- Mr. Sank's tenure on the Board was 18 years.
- The resignation is not attributed to any disagreement with the Company.
- The report is signed by Nadav Kidron, President and CEO.